OncoMatch/Clinical Trials/NCT06449781
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Is NCT06449781 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lutetium (177Lu) vipivotide tetraxetan for prostate cancer.
Treatment: Lutetium (177Lu) vipivotide tetraxetan — Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radical locoregional treatment
Completion of radical locoregional treatment
Lab requirements
Blood counts
neutrophils > 1500x10^9/l; thrombocytes > 100,000x10^9/l; hemoglobin > 9 g/dl
Kidney function
egfr > 50 ml/min; albumin >2.5 mg/ml
Liver function
bilirubin < 2xuln (gilbert's syndrome < 5xuln); aminotransferase < 3xuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify